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The Editorial on the Research Topic
Current Concepts of Cellular and Biological Drugs to Modulate Regulatory T Cell Activity 
in the Clinic
Regulatory T (Treg) cells are essential for the maintenance of peripheral tolerance and prevent 
the development of autoimmunity and allergy. While on the one hand being indispensable for the 
perpetuation of tolerance to harmless antigens or self-antigens, Treg cells contribute to cancer patho-
genesis and progression (1). Hence, the potential to treat a multitude of different human diseases by 
pharmacological modulation of Treg cells is enormous. Consequently, this T cell population is in the 
focus of biomedical research and development. Currently, isolated and in vitro expanded Treg cells as 
cellular therapeutics are intensively tested in clinical trials for their ability to prevent and ameliorate 
graft-versus-host disease (GvHD) and first biologicals to modulate Treg cell activity directly in man 
are being developed and tested in preclinical and clinical trials.
This Research Topic comprised seven review articles; the authors discuss selected developments 
on the way from basic research on manipulation of peripheral tolerance mechanisms toward clinical 
application.
Mahnke et al. present an updated view on the critical role of dendritic cells (DC) in control and 
maintenance of peripheral tolerance under non-inflammatory conditions based on findings obtained 
in preclinical mouse models showing that factors of local microenvironment and extrinsic inflam-
matory signals dictate the function of these “sentinels of immunity” (2): inducers of tolerance versus 
immunity. Analogous to this overview of basic DC research in the mouse, Raker et al. provide an 
overview of translational research on human tolerogenic DC, the important role of IL-10 for stability of 
their phenotype and their potential as cellular therapeutics for reestablishment of peripheral tolerance 
in patients with autoimmune or allergic diseases (Raker et al.). Hahn et al. discuss current develop-
ments in establishment of humanized mouse models for preclinical testing of novel biologicals to 
manipulate Treg cell suppressive function in vivo. Additionally, the risk and benefit of cellular therapies 
using in vitro expanded Treg cells or pharmacological modulators of Treg cell function like rapamycin 
or IL-2 is comparatively discussed by Perdigoto et al. Complementary, Pham et al. provide an updated 
view on the use of low dose IL-2 in combination with tissue-specific antigens as a therapeutic approach 
to expand and activate antigen-specific Treg cells in patients with type I diabetes (Pham et al.), an 
approach that will be currently used by different groups for treatment of T cell-mediated autoimmunity. 
A well-known strategy for tolerance induction first described by Hermann Waldman’s group in 1990 
is the application of non-depleting anti-CD4 antibodies that induces a long lasting antigen-specific 
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tolerance in mouse models of solid organ transplantation (3). In this 
Research Topic, König et al. report on their clinical experiences by 
using a humanized anti-CD4 antibody (BT-061, Tregalizumab) for 
treatment of rheumatoid arthritis in patients. This anti-CD4 mAb, 
first tested in patients with psoriasis, induces suppressive function 
of human Treg without blocking T helper cell activities per  se. 
Additionally, Hui et al. discuss recent advances of management of 
advanced non-small cell lung cancer by PD-1-blocking antibodies 
and their impact on cytokine-induced killer cell activity. In sum-
mary, this Research Topic of Frontiers in Immunology provides 
a snapshot of our recent understanding of Treg cell biology and 
function with a special focus on current concepts of therapeutic 
strategies to modulate peripheral tolerance mechanisms and Treg 
cell activity in humans. Given the recent advances in our under-
standing of the molecular mechanisms underlying cell type- and 
 tissue-specific Treg cell function, it seems promising that Treg cell-
based cellular therapeutics as well as novel biologicals to directly 
and cell-specifically modulate Treg cell function are entering the 
clinic, and first results of their potential as tolerance modifiers will 
be available in near future.
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